Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01895972 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
NCT01895972 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 130 participants.
The verdict
NCT01895972, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
Study Summary
The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.
Interventions
- DRUG Latanoprostene bunod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2013-07-05 |
| Est. Completion | 2015-04-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01895972
The ClinicalTrials.gov registry entry for NCT01895972 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Latanoprostene bunod is the first listed.
NCT01895972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01895972 about?
NCT01895972 is a clinical study titled "Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT". The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.
What is the current status of trial NCT01895972?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2013-07-05. Estimated completion is 2015-04-14.
What interventions are being tested in trial NCT01895972?
The interventions under investigation include: Latanoprostene bunod (DRUG).
Who is sponsoring clinical trial NCT01895972?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.